CCR8

C-C chemokine receptor type 8 · P51685 · CCR8 on Sugi Atlas →

59,750 patent compounds predicted against CCR8, 26,653 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL371564	1.00	6/20
Phenanthroline (SCHEMBL226209)	0.73	6/20
SCHEMBL412974	0.69	6/20
SCHEMBL250356	0.57	6/20
Phenanthroline (SCHEMBL8312)	1.00	5/20
SCHEMBL136654	1.00	5/20
SCHEMBL182930	1.00	5/20
Phenanthroline (SCHEMBL44857)	0.94	5/20
Phenanthroline (SCHEMBL345410)	0.94	5/20
Phenanthroline (SCHEMBL343516)	0.80	5/20
Phenanthroline (SCHEMBL343946)	0.80	5/20
Phenanthroline (SCHEMBL344595)	0.80	5/20
Phenanthroline (SCHEMBL407390)	0.76	5/20
Phenanthroline (SCHEMBL497012)	0.76	5/20
1-Naphthoquinoline (SCHEMBL15106)	0.68	5/20
1-Naphthoquinoline (SCHEMBL262791)	0.65	5/20
SCHEMBL67041	0.64	5/20
SCHEMBL67915	0.64	5/20
SCHEMBL8313	0.62	5/20
SCHEMBL169671	0.62	5/20

Clinical trials — most relevant to CCR8 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Study of Azithromycin for Lymphocytic Bronchiolitis/Bronchitis After Lung Transplantation	PHASE4	COMPLETED
Effects of Allopurinol on Inflammation and Ultrasonographic Changes in People With Elevated Uric Acid But no Symptoms	PHASE3	UNKNOWN
Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab in Metastatic Carcinoma of the Cervix	PHASE3	COMPLETED
Assessment the Activity Value of Isotretinoin (13- Cis-Retinoic Acid ) in the Treatment of COVID-19 ( Isotretinoin in Treatment of COVID-19) (Randomized)	PHASE3	UNKNOWN
Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta Trap/PD-L1) With CV301 TRICOM in Advanced Solid Tumors (STAT)	PHASE1/PHASE2	COMPLETED
Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer (N-Dur)	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Aerosol Combination Therapy of All-trans Retinoic Acid and Isotretinoin as A Novel Treatment for Inducing Neutralizing Antibodies in COVID -19 Infected Patients Better Than Vaccine : An Innovative Treatment	PHASE2	UNKNOWN
IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Newly Diagnosed and Recurrent Pediatric High-grade Glioma (pHGG) and Newly Diagnosed Diffuse Intrinsic Pontine Glioma (ndDIPG)	PHASE1	NOT_YET_RECRUITING
A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)	PHASE1	RECRUITING
RP72 Monotherapy and in Combination With Gemcitabine in Patients With Pancreatic Cancer	PHASE1	UNKNOWN
Placebo-controlled Assessment of the Effect of a Food Supplement on Skin Protection After Exposure to UV Radiation	PHASE1	COMPLETED
U69-CART-Cells For R/R T-ALL	PHASE1	RECRUITING
IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Adult Glioblastoma	PHASE1	RECRUITING
The Role of SDF-1/CXCR4 in Metastasis of Oral Squamous Cell Carcinoma	nan	UNKNOWN
Circular RNA and Chemerin in Breast Cancer Patient	nan	UNKNOWN
The Role of MMPs in the CXCL12-Induced Invasion of Laryngeal and Hypopharyngeal Squamous Cell Carcinoma	nan	UNKNOWN
Evaluation of CCR6 Gene Expression and Circulating CCL20 Levels as Potential Biomarkers in Rheumatoid Arthritis	nan	NOT_YET_RECRUITING
Value of Various Chemokines in the Detection and Follow up of RCC	nan	UNKNOWN
Nivolumab in mRCC Patients: Treg Function, T-cell Access and NK Interactions to Predict and Improve Efficacy	nan	COMPLETED
IL-11 in the Development of Multiple Sclerosis	nan	UNKNOWN
Inflammatory Biomarkers in Psychogenic Non-epileptic Seizure	nan	UNKNOWN
IL6&8 in Malnourished Children With Acute Diarrhea	nan	UNKNOWN
Measuring the Healthy Pediatric Inflammatory Response to Vaccination.	nan	ENROLLING_BY_INVITATION
The Relationship Between Serum Chemokine Ligand 21 (CCL-21) Level and Disease Activity	nan	NOT_YET_RECRUITING
C-X-C Chemokine Receptor 4 in Chronic Lymphocytic Leukemia	nan	UNKNOWN
The Role of Stromal Cell-Derived Factor-1 (SDF-1)/CXC Chemokine Receptor 4 (CXCR4) in Metastasis of Laryngeal and Hypopharyngeal Squamous Cell Carcinoma	nan	UNKNOWN
Lung-Resident Memory Th2 Cells in Asthma	nan	ACTIVE_NOT_RECRUITING
The Role of CD4+ T Cell Subsets in the Mechanism of Action of Vedolizumab in Ulcerative Colitis	nan	UNKNOWN
Evaluating Urinary CXCL10 for Enhanced Detection of Acute Rejection in Kidney Transplant Patients With Low DD-CFDNA	nan	RECRUITING
Inflammatory Biomarkers in Seizure	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a CCR8 binder may also engage these)

Protein	Name	Similarity
Q95ND1	—	0.997	Q95ND1 →
P61815	—	0.996	P61815 →
CCR4	C-C chemokine receptor type 4	0.995	landscape →
Q9TV48	—	0.995	Q9TV48 →
Q95NE8	—	0.994	Q95NE8 →
P56439	—	0.994	P56439 →
P61755	—	0.994	P61755 →
O97665	—	0.994	O97665 →
O97881	—	0.992	O97881 →
CCR7	C-C chemokine receptor type 7	0.991	landscape →
Q95NC3	—	0.990	Q95NC3 →
Q5MD62	—	0.990	Q5MD62 →
O97962	—	0.990	O97962 →
O97880	—	0.990	O97880 →
Q2KTE1	—	0.989	Q2KTE1 →
P61757	—	0.989	P61757 →
O97879	—	0.989	O97879 →
P47774	—	0.989	P47774 →
Q95NC1	—	0.988	Q95NC1 →
O97883	—	0.988	O97883 →
P56482	—	0.988	P56482 →
CCR1	C-C chemokine receptor type 1	0.988	landscape →
O62743	—	0.988	O62743 →
O97882	—	0.988	O97882 →
Q9N0Z0	—	0.987	Q9N0Z0 →
Q9TV49	—	0.987	Q9TV49 →
Q95ND2	—	0.987	Q95ND2 →
P56484	—	0.987	P56484 →
Q9XT76	—	0.987	Q9XT76 →
Q95ND0	—	0.987	Q95ND0 →